Skip to main content
Top
Published in: Infection 6/2014

01-12-2014 | Original Paper

Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients?

Authors: K. S. R. Massaro, R. Macedo, B. S. de Castro, F. Dulley, M. S. Oliveira, M. A. S. Yasuda, A. S. Levin, S. F. Costa

Published in: Infection | Issue 6/2014

Login to get access

Abstract

Background

The morbidity and mortality in hematopoietic stem cell transplantation (HSCT) occur due to infectious complications and constitute the major clinical problems in HSCT recipients. The role of the use of biomarkers in post-HSCT patients is still controversial.

Objectives

To assess the serum values of biomarkers interleukin 6 (IL-6), procalcitonin (PCT) and C-reactive protein (CRP) and risk factors for post-HSCT death.

Patients and methods

Prospective study conducted in patients submitted to HSCT at a university hospital. Biomarkers (IL-6, PCT and CRP) were assessed on the day afebrile neutropenia was detected, in the febrile event, 24 and 72 h after fever onset and 48 h or 5 days if fever persisted. Patients were compared as to the death outcome within 30 days from the HSCT. Variables with p < 0.15 were included in the multivariate analysis model (MVA) that were performed for all patients included in the study and separated for autologous and allogeneic HSCT patients.

Results

296 patients with ages ranging between 15 and 70 years, neutropenic, submitted to HSCT, being 216 (73 %) autologous and 80 (20 %) allogeneic were assessed. One hundred and ninety (64.2 %) patients presented fever after the transplantation and infection microbiologically controlled in 78 (26.4 %). Twenty-three cases (7.8 %) evolved to death. The risk factors associated with death in the bivariate analysis were age, allogeneic transplantation, unrelated transplantation, GVHD, bloodstream infection by Gram-negative, IL-6 >140 pg/mL and CRP ≥120 mg/L and the protective ones were lymphoma and hospital outpatient support. The independent variables in the MVA associated with death were allogeneic and unrelated transplantation, blood stream infection (BSI) by Gram-negative, LDH ≥390 UI/L, urea ≥25 mg/dL and CRP ≥120 mg/L for HSCT transplanted patients and BSI due to Gram-negative and CRP ≥120 mg/L for allogeneic HSCT, however, CRP ≥120 mg/L did not remain in the model when urea ≥25 mg/L was included. No independent risk factor was found for autologous patients.

Conclusions

Out of the biomarkers assessed, only CRP ≥120 mg/L was independently associated with death. Other risk factors found were: type of transplantation (allogeneic and unrelated), bloodstream infection by Gram-negative, LDH ≥390 UI/L and urea ≥25 mg/dL. For allogeneic patients only CRP ≥120 mg/L and BSI due to Gram-negative were risk factors for death; however, CRP did not remain in the model when urea ≥25 mg/L was included.
Literature
1.
go back to reference Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979–86.PubMed Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979–86.PubMed
2.
go back to reference Sorely JS, Shea TC. Prevention of infections in bone marrow transplant recipients. Infect Dis Clin North Am. 1997;11:459–77.CrossRef Sorely JS, Shea TC. Prevention of infections in bone marrow transplant recipients. Infect Dis Clin North Am. 1997;11:459–77.CrossRef
3.
go back to reference Love LJ, Schimpff SC, Schiffer CA, Wiernik PH. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med. 1980;68:643–8.PubMedCrossRef Love LJ, Schimpff SC, Schiffer CA, Wiernik PH. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med. 1980;68:643–8.PubMedCrossRef
6.
go back to reference Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999;18:283–5.PubMedCrossRef Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999;18:283–5.PubMedCrossRef
7.
go back to reference Südhoff T, Giagounidis A, Karthaus M. Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy. 2000;46:77–85.PubMedCrossRef Südhoff T, Giagounidis A, Karthaus M. Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy. 2000;46:77–85.PubMedCrossRef
8.
go back to reference Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol. 2000;111:1093–102.PubMedCrossRef Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol. 2000;111:1093–102.PubMedCrossRef
9.
go back to reference Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.PubMedCrossRef Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.PubMedCrossRef
10.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical Practice Guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:56–93.CrossRef Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical Practice Guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:56–93.CrossRef
11.
go back to reference Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101–11.PubMedCrossRef Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101–11.PubMedCrossRef
12.
go back to reference EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86:668–72.CrossRef EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86:668–72.CrossRef
13.
go back to reference Pihusch M, Pihusch R, Fraunberger P. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol. 2006;76:93–101.PubMedCrossRef Pihusch M, Pihusch R, Fraunberger P. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol. 2006;76:93–101.PubMedCrossRef
14.
go back to reference Brodska H, Drabek T, Malickova K, Kazda A, Vitek A, Zima T, Markova M. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care. 2008;13:1–7. Brodska H, Drabek T, Malickova K, Kazda A, Vitek A, Zima T, Markova M. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care. 2008;13:1–7.
15.
go back to reference Bacigalupo A, Oneto R, Bruno B, Soracco M, Lamparelli T, Gualandi F, et al. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transplant. 1999;24:653–9.PubMedCrossRef Bacigalupo A, Oneto R, Bruno B, Soracco M, Lamparelli T, Gualandi F, et al. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transplant. 1999;24:653–9.PubMedCrossRef
16.
go back to reference Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol. 1998;16:3796–802.PubMed Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol. 1998;16:3796–802.PubMed
17.
go back to reference Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715–26.PubMedCrossRef Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715–26.PubMedCrossRef
18.
go back to reference Mikulska M, Del Bono V, Bruzzi P, Raiola AM, Gualandi F, Van Lint MT, et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection. 2012;40:271–8.PubMedCrossRef Mikulska M, Del Bono V, Bruzzi P, Raiola AM, Gualandi F, Van Lint MT, et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection. 2012;40:271–8.PubMedCrossRef
19.
go back to reference Blennow O, Ljungman P, Sparrelid E, Mattsson J, Remberger M. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transpl Infect Dis. 2014;16:106–14.PubMedCrossRef Blennow O, Ljungman P, Sparrelid E, Mattsson J, Remberger M. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transpl Infect Dis. 2014;16:106–14.PubMedCrossRef
20.
go back to reference Piñana JL, Montesinos P, Martino R, Vazquez L, Rovira M, López J, et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol. 2014;93:299–307.PubMedCrossRef Piñana JL, Montesinos P, Martino R, Vazquez L, Rovira M, López J, et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol. 2014;93:299–307.PubMedCrossRef
21.
go back to reference Mendes ET, Dulley F, Basso M, Batista MV, Coracin F, Guimarães T, et al. Healthcare-associated infection in hematopoietic stem cell transplantation patients: risk factors and impact on outcome. Intern J Infect Dis. 2012;16:424–8.CrossRef Mendes ET, Dulley F, Basso M, Batista MV, Coracin F, Guimarães T, et al. Healthcare-associated infection in hematopoietic stem cell transplantation patients: risk factors and impact on outcome. Intern J Infect Dis. 2012;16:424–8.CrossRef
22.
go back to reference Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, et al. Pretreatment C-Reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Blood Marrow Transplant. 2008;14:1209–16.CrossRef Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, et al. Pretreatment C-Reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Blood Marrow Transplant. 2008;14:1209–16.CrossRef
23.
go back to reference Kanda J, Mizumoto C, Ichinohe T, Kawabata H, Saito T, Yamashita K, Kondo T, Takakura S, Ichiyama S, Uchiyama T, Ishikawa T. Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;3:1–9. Kanda J, Mizumoto C, Ichinohe T, Kawabata H, Saito T, Yamashita K, Kondo T, Takakura S, Ichiyama S, Uchiyama T, Ishikawa T. Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;3:1–9.
24.
go back to reference Ortega M, Rovira M, Almela M, de la Bellacasa JP, Carreras E, Mensa J. Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant. 2004;33:741–4.PubMedCrossRef Ortega M, Rovira M, Almela M, de la Bellacasa JP, Carreras E, Mensa J. Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant. 2004;33:741–4.PubMedCrossRef
25.
go back to reference Schots R, Kaufman L, van Riet I, Othman TB, De Waele M, Van Camp B, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003;17:1150–6.PubMedCrossRef Schots R, Kaufman L, van Riet I, Othman TB, De Waele M, Van Camp B, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003;17:1150–6.PubMedCrossRef
26.
go back to reference Koya J, Nannya Y, Ichikawa M, Kurokawa M. The clinical role of procalcitonin in hematopoietic SCT. Bone Marrow Transplant. 2012;47:1326–31.PubMedCrossRef Koya J, Nannya Y, Ichikawa M, Kurokawa M. The clinical role of procalcitonin in hematopoietic SCT. Bone Marrow Transplant. 2012;47:1326–31.PubMedCrossRef
27.
go back to reference Azarpira N, Ramzi M, Aghdaie M, Daraie M. Procalcitonin and C-reactive protein serum levels after hematopoietic stem-cell transplant. Exp Clin Transplant. 2009;2:115–8. Azarpira N, Ramzi M, Aghdaie M, Daraie M. Procalcitonin and C-reactive protein serum levels after hematopoietic stem-cell transplant. Exp Clin Transplant. 2009;2:115–8.
28.
go back to reference Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–17.PubMedCrossRef Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–17.PubMedCrossRef
29.
go back to reference Christ-Crain M, Jaccard-Stolz D, Bingisser R. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–7.PubMedCrossRef Christ-Crain M, Jaccard-Stolz D, Bingisser R. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–7.PubMedCrossRef
30.
go back to reference Charles PE, Tinel C, Barbar S. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care. 2009;13:R38.PubMedCentralPubMedCrossRef Charles PE, Tinel C, Barbar S. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care. 2009;13:R38.PubMedCentralPubMedCrossRef
31.
go back to reference Blijlevens NMA, Donnelly JP, Meis FGM, De Keizer MH, De Pauw BE. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol. 2000;7:889–92.PubMedCentralPubMed Blijlevens NMA, Donnelly JP, Meis FGM, De Keizer MH, De Pauw BE. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol. 2000;7:889–92.PubMedCentralPubMed
32.
go back to reference Mori Y, Miyawaki K, Kato K, Takenaka K, Iwasaki H, Harada N, Miyamoto T, Akashi K, et al. Diagnostic value of serum procalcitonin and C-reactive protein for infections after allogeneic hematopoietic stem cell transplantation versus nontransplant setting. Inter Med. 2011;50:2149–55.CrossRef Mori Y, Miyawaki K, Kato K, Takenaka K, Iwasaki H, Harada N, Miyamoto T, Akashi K, et al. Diagnostic value of serum procalcitonin and C-reactive protein for infections after allogeneic hematopoietic stem cell transplantation versus nontransplant setting. Inter Med. 2011;50:2149–55.CrossRef
33.
go back to reference Schots R, Van Riet I, Othman TB, Trullemans F, de Waele M, Van Camp B, et al. An early increase in serum levels of C-reactive protein is an Independent risk factor for the occurrence of major complications and 100- Day transplant-related mortality after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2002;30:441–6.PubMedCrossRef Schots R, Van Riet I, Othman TB, Trullemans F, de Waele M, Van Camp B, et al. An early increase in serum levels of C-reactive protein is an Independent risk factor for the occurrence of major complications and 100- Day transplant-related mortality after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2002;30:441–6.PubMedCrossRef
Metadata
Title
Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients?
Authors
K. S. R. Massaro
R. Macedo
B. S. de Castro
F. Dulley
M. S. Oliveira
M. A. S. Yasuda
A. S. Levin
S. F. Costa
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 6/2014
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0685-2

Other articles of this Issue 6/2014

Infection 6/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.